This program delivers high-affinity antibodies designed to neutralize Arginase-1, effectively reversing the nutrient-depletion-mediated suppression of T-cells and restoring microenvironment metabolic activity.
Learn More →Next-IO™ TAM related Therapeutics
Creative Biolabs provides a specialized suite of drug discovery services focused on the TAM receptor axis to modulate the innate immune system within the tumor microenvironment. We provide high-affinity lead candidates, customized antibody engineering, and advanced functional validation assays. By partnering with us, clients gain access to specialized myeloid-modulating tools and biological insights that facilitate the identification of novel therapeutic leads, overcome immune-suppressive barriers in research models, and provide a clear path for the development of next-generation oncology pipelines.
Introduction What We Can Offer How We Can Help Why Choose Us Customer Reviews FAQs Related Services Contact Us
Introduction of Next-IO™ TAM-Related Therapeutics
TAM receptors (Tyro3, AXL, MerTK) are critical homeostatic regulators that are exploited within the microenvironment to suppress inflammation and clear apoptotic debris "silently" (efferocytosis). Research identifies these as premier "innate checkpoints." By targeting the Vitamin K-dependent γ-carboxylation of ligands or the receptor-ligand bridge, Creative Biolabs' Next-IO™ therapeutics break this cycle of suppression, re-polarizing the microenvironment to support active adaptive immunity and NK cell-mediated responses in research settings.
Request a Consultation →
Fig.1 Functions and mediators of TAMs in tumor progression. 1
What We Can Offer
One-stop therapeutic development
We manage the full lifecycle from early laboratory-scale lead identification through to pilot-scale and large-scale production, ensuring a seamless transition across all research development stages.
Highly customizable antibody formats
Our engineering platform constructs various multi-specific antibodies and specialized fragments tailored to overcome the unique physical and immunological barriers of your specific tumor research challenges.
Large-scale industrial bioprocessing
Access our extensive fermentation and bioreactor network, providing a robust and reliable supply for the most demanding and large-scale research initiatives.
Cell bank characterization
We conduct rigorous testing to guarantee the genetic and phenotypic stability of your expression strains, ensuring consistent product quality throughout repeated and long-term fermentation cycles.
How Creative Biolabs Can Assist Your Project
Next-IO™ Anti-ARG1 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-CEA × CD3 Therapeutic Bispecific Antibody Program
We engineer bispecific molecules that facilitate direct interaction between CEA-positive tumor cells and CD3-positive T-cells, circumventing the need for traditional antigen presentation.
Learn More →Next-IO™ Anti-FASL Therapeutic scFv Antibody Program
This initiative provides specialized scFv constructs to block FAS-Ligand interactions, protecting infiltrating immune cells from apoptosis and sustaining the active immune response within the niche.
Learn More →Next-IO™ Anti-FRα Therapeutic Monoclonal Antibody Program
Our platform generates high-affinity antibodies targeting Folate Receptor alpha, allowing for precise identification and research into tumor cells overexpressing this specific surface marker.
Learn More →Next-IO™ Anti-FRα Antibody-Drug Conjugate Program
Combining our anti-FRα leads with potent research-grade payloads, this program offers sophisticated tools to evaluate the efficacy of targeted delivery in folate-receptor-rich microenvironments.
Learn More →Next-IO™ CSF1/CSF1R Axis Targeted Therapeutic Antibody Program
We provide antibodies that disrupt CSF1R signaling to inhibit the recruitment and survival of suppressive macrophages, fundamentally altering the myeloid composition of research models.
Learn More →Next-IO™ Anti-TLR Therapeutic Monoclonal Antibody Program
This program focuses on modulating Toll-like Receptor signaling within the microenvironment to trigger innate activation and enhance the efficacy of combined immunotherapeutic research leads.
Learn More →Next-IO™ Anti-STAT3 Therapeutic Monoclonal Antibody Program
Our STAT3-targeted antibodies offer a mechanism to disrupt the master transcriptional regulator of the M2-like phenotype, facilitating the research-based re-polarization of macrophages toward inflammatory states.
Learn More →Next-IO™ Anti-HCK Therapeutic Monoclonal Antibody Program
By targeting Hematopoietic Cell Kinase, this program assists in the research of myeloid-specific signaling pathways that drive tumor progression and immune exclusion in "cold" models.
Learn More →Next-IO™ Anti-IL-1/IL-1R Axis Targeted Therapeutic Antibody Program
We offer leads that neutralize the IL-1 axis, helping to mitigate the chronic inflammatory signals that support tumor growth and suppressive myeloid cell recruitment.
Learn More →Highlights
Targeting Excellence
Our expertise in the complex dynamics of the TAM axis allows us to design leads that fundamentally reset the immune landscape rather than providing simple, one-dimensional receptor inhibition.
Unrivaled Specificity
We offer high selectivity for specific receptors, ensuring precise targeting while avoiding interference with natural homeostatic pathways, thereby maintaining the biological integrity of your research models and internal pathways.
Functional Re-polarization
Our programs are designed to re-educate the immune compartment, converting internal repair mechanisms into active anti-tumor responses to overcome the barriers typically found in resistant or cold tumor environments.
Evidence-Based Success
Our methodologies demonstrate proven performance in difficult research models, effectively improving immune cell ratios and overcoming suppressive biological barriers to ensure your oncology pipeline is built on verified results.
Reach out to our experts to discuss your specific targets and receive a customized service quote today.
Customer Reviews
-
Superior Receptor Precision
High-affinity antibodies from this program allowed us to precisely block MerTK in syngeneic models without systemic disruption. While high-ligand environments require careful titration, the resulting M2-to-M1 shift significantly surpassed standard inhibitors. - Dr. E**a. M. -
Cold Tumor Activation
Implementing these bispecific leads successfully addressed our T-cell infiltration issues. This re-education strategy effectively pivoted myeloid function while maintaining population integrity, offering a robust solution for early-stage pipeline microenvironment validation studies. - J**n. T.
FAQs
Can these therapeutics be combined with existing checkpoint inhibitors?
Yes. Our TAM-targeted leads are specifically designed to address innate immune resistance in research models, making them excellent candidates for combination studies alongside standard adaptive immune checkpoint inhibitors.
How do your TAM inhibitors compare to traditional kinase inhibitors?
Traditional inhibitors are often small molecules with broader profiles. Our Next-IO™ programs utilize large-molecule biologics to target extracellular domains, providing superior specificity and significantly reducing off-target interactions in research.
Related Services
Next-IO™ Anti-CD11b Therapeutic Monoclonal Antibody Program
Advanced analysis of MDSC recruitment and myeloid adhesion dynamics. This service evaluates how lead candidates influence the trafficking of suppressive cells into the tumor niche.
Learn More →Next-IO™ IL-4R Therapeutic Fusion Protein Program
Comprehensive screening of fusion proteins to quantify inhibition of IL-4/IL-13 mediated STAT6 phosphorylation. This ensures effective disruption of M2 macrophage polarization pathways.
Learn More →How to Contact Us
Creative Biolabs' Next-IO™ TAM-Related Therapeutics represent a definitive shift in research strategy, moving beyond the conventional focus on T-cell exhaustion to address the critical innate roots of tumor immunity. By centering our approach on the re-polarization of the myeloid compartment, we help researchers dismantle the underlying architecture of immune evasion.
We invite you to explore how our specialized tools can be tailored to meet your unique program objectives, please reach out to our team.
Reference
- Kzhyshkowska, Julia et al. "Targeting of TAMs: can we be more clever than cancer cells?." Cellular & molecular immunology vol. 21,12 (2024): 1376-1409. Distributed under an Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s41423-024-01232-z
Download our brochureLoading case studies...
Online Inquiry